In_vitro_activity_of_sparfloxacin_(CI-978;_AT-4140)_against_clinical_isolates_from_cancer_patients._The_in_vitro_activity_of_sparfloxacin,_a_new_quinolone,_was_compared_with_those_of_ciprofloxacin_and_fleroxacin_against_gram-positive_and_gram-negative_bacteria,_greater_than_90%_of_which_were_isolated_from_blood_culture_specimens_of_cancer_patients._Sparfloxacin_was_extremely_active_against_Acinetobacter_species,_Aeromonas_hydrophila,_Citrobacter_diversus,_Enterobacter_species,_Escherichia_coli,_Klebsiella_species,_Proteus_vulgaris,_and_Serratia_marcescens_(inhibiting_greater_than_90%_of_these_isolates_at_a_concentration_of_0.5_microgram/ml)_and_moderately_active_against_Pseudomonas_species,_other_Proteus_species,_and_Citrobacter_freundii._Sparfloxacin_inhibited_greater_than_90%_of_staphylococci_(including_methicillin-resistant_and_coagulase-negative_strains)_at_a_concentration_of_0.12_microgram/ml_and_greater_than_90%_of_streptococci_(including_Streptococcus_pneumoniae)_at_a_concentration_of_1.0_microgram/ml._It_was_also_active_against_Bacillus_cereus,_Enterococcus_species,_and_Corynebacterium_jeikeium,_organisms_that_have_become_fairly_common_in_cancer_patients.